Long-term surveillance study of rituximab originator treated patients with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA)

Journal article

Lay Summary: What does this mean for patients? Rituximab is used to treat active disease and to prevent relapses in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV). Serious complications, including infections, low natural antibody levels, cancers, low white blood cell levels, heart disease and blood clots are common in AAV patients in general. Whether these complications are more or less common with rituximab is unclear. This study assessed the frequency of serious complications and compared time to first serious complications between patients, either treated with or without rituximab. Over 40% of the patients in this study experienced at least one serious complication. Overall, first serious complication occurred earlier and higher risk of serious infection was seen in rituximab patients. However, these findings should be interpreted with caution as the rituximab patients had been diagnosed with vasculitis for longer and had received a greater amount of immunosuppression in the past, compared with the patients who had not been treated with rituximab.

Authors: Uchida, L; Jones, RB; Smith, RM; Nodale, M; Bond, S

• Publication status: Published
• Peer review status: Peer reviewed
• Publisher: Oxford University Press
• Journal: Rheumatology Advances in Practice
• Volume: 8
• Issue: 3
• Article number: rkae090
• Publication date: 2024-08-06
• Acceptance date: 2024-07-15
• DOI: 10.1093/rap/rkae090
• EISSN: 2514-1775
• Language: English
• Keywords: safety; rituximab; ANCA-associated vasculitis